192
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Epratuzumab for systemic lupus erythematosus

Evaluation of: Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 2014;53(3):502-11

, MD PhD

Bibliography

  • Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365(22):2110-21
  • Trials C. Study of Epratuzumab versus placebo in subjects with moderate to severe general systemic lupus erythematosus (EMBODY 1). 2014. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01262365?term=embody&rank=1
  • Strand V, Petri M, Kalunian K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) 2014;53(3):502-11
  • Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013;52(7):1313-22

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.